Rhenman & Partners Asset Management AB
Latest statistics and disclosures from Rhenman & Partners Asset Management AB's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BSX, LLY, PRCT, ISRG, REGN, and represent 17.78% of Rhenman & Partners Asset Management AB's stock portfolio.
- Added to shares of these 10 stocks: ZBH (+$13M), CI (+$10M), BIIB (+$8.7M), JAZZ (+$6.5M), HUM (+$6.1M), INSP (+$5.2M), CNC, PODD, UHS, NBIX.
- Started 2 new stock positions in ASTH, ZBH.
- Reduced shares in these 10 stocks: NTRA (-$17M), BDX (-$15M), BSX (-$13M), HCA (-$13M), GKOS (-$11M), COO (-$10M), GILD (-$10M), ELV (-$10M), ABBV (-$9.4M), MDT (-$7.9M).
- Sold out of its positions in BBIO, DXCM, EPIX, EVH, MDGL.
- Rhenman & Partners Asset Management AB was a net seller of stock by $-137M.
- Rhenman & Partners Asset Management AB has $973M in assets under management (AUM), dropping by -21.03%.
- Central Index Key (CIK): 0001599882
Tip: Access up to 7 years of quarterly data
Positions held by Rhenman & Partners Asset Management AB consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Rhenman & Partners Asset Management AB
Rhenman & Partners Asset Management AB holds 92 positions in its portfolio as reported in the December 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Boston Scientific Corporation (BSX) | 4.1 | $40M | -24% | 444k | 89.32 |
|
| Eli Lilly & Co. (LLY) | 3.6 | $35M | -4% | 46k | 772.00 |
|
| Procept Biorobotics Corp (PRCT) | 3.5 | $34M | -5% | 420k | 80.52 |
|
| Intuitive Surgical Com New (ISRG) | 3.4 | $33M | 64k | 521.96 |
|
|
| Regeneron Pharmaceuticals (REGN) | 3.2 | $31M | +11% | 44k | 712.33 |
|
| UnitedHealth (UNH) | 3.1 | $31M | -16% | 61k | 505.86 |
|
| Inspire Med Sys (INSP) | 2.9 | $28M | +22% | 150k | 185.38 |
|
| Merck & Co (MRK) | 2.8 | $28M | +15% | 278k | 99.48 |
|
| EXACT Sciences Corporation (EXAS) | 2.7 | $27M | 471k | 56.19 |
|
|
| Tenet Healthcare Corp Com New (THC) | 2.6 | $25M | -10% | 198k | 126.23 |
|
| Gilead Sciences (GILD) | 2.4 | $24M | -30% | 256k | 92.37 |
|
| Abbvie (ABBV) | 2.3 | $22M | -29% | 124k | 177.70 |
|
| Cigna Corp (CI) | 2.2 | $22M | +88% | 78k | 276.14 |
|
| Medtronic SHS (MDT) | 2.2 | $22M | -26% | 270k | 79.88 |
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 2.1 | $20M | +4% | 50k | 402.70 |
|
| Alignment Healthcare (ALHC) | 2.0 | $20M | -10% | 1.8M | 11.25 |
|
| Natera (NTRA) | 2.0 | $20M | -46% | 123k | 158.30 |
|
| McKesson Corporation (MCK) | 2.0 | $19M | +13% | 34k | 569.91 |
|
| Biogen Idec (BIIB) | 1.9 | $19M | +84% | 124k | 152.92 |
|
| Oscar Health Cl A (OSCR) | 1.9 | $18M | 1.4M | 13.44 |
|
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 1.8 | $18M | +56% | 146k | 123.15 |
|
| BioMarin Pharmaceutical (BMRN) | 1.7 | $17M | -31% | 251k | 65.73 |
|
| Royalty Pharma Shs Class A (RPRX) | 1.6 | $15M | -3% | 595k | 25.51 |
|
| Insulet Corporation (PODD) | 1.5 | $15M | +42% | 57k | 261.07 |
|
| Intra Cellular Therapies (ITCI) | 1.5 | $15M | -14% | 176k | 83.52 |
|
| Danaher Corporation (DHR) | 1.5 | $15M | -23% | 64k | 229.55 |
|
| Abbott Laboratories (ABT) | 1.5 | $15M | -5% | 128k | 113.11 |
|
| Humana (HUM) | 1.4 | $14M | +78% | 55k | 253.71 |
|
| Neurocrine Biosciences (NBIX) | 1.4 | $14M | +39% | 100k | 136.50 |
|
| Zimmer Holdings (ZBH) | 1.3 | $13M | NEW | 124k | 105.63 |
|
| AmerisourceBergen (COR) | 1.2 | $12M | +19% | 54k | 224.68 |
|
| CVS Caremark Corporation (CVS) | 1.2 | $12M | +45% | 268k | 44.89 |
|
| Centene Corporation (CNC) | 1.2 | $12M | +67% | 196k | 60.58 |
|
| Becton, Dickinson and (BDX) | 1.1 | $11M | -57% | 48k | 226.87 |
|
| Dynavax Technologies Corp Com New (DVAX) | 1.1 | $11M | -29% | 839k | 12.77 |
|
| Cooper Cos (COO) | 1.1 | $11M | -49% | 115k | 91.93 |
|
| Axsome Therapeutics (AXSM) | 1.1 | $10M | 123k | 84.61 |
|
|
| Hca Holdings (HCA) | 1.1 | $10M | -54% | 34k | 300.15 |
|
| Molina Healthcare (MOH) | 1.0 | $10M | +15% | 34k | 291.05 |
|
| Iovance Biotherapeutics (IOVA) | 0.9 | $9.1M | +17% | 1.2M | 7.40 |
|
| Janux Therapeutics (JANX) | 0.9 | $9.1M | +59% | 170k | 53.54 |
|
| Align Technology (ALGN) | 0.9 | $8.7M | -23% | 42k | 208.51 |
|
| Anthem (ELV) | 0.9 | $8.5M | -54% | 23k | 368.90 |
|
| Thermo Fisher Scientific (TMO) | 0.8 | $8.1M | -37% | 16k | 520.23 |
|
| Stryker Corporation (SYK) | 0.8 | $8.1M | -2% | 23k | 360.05 |
|
| Tg Therapeutics (TGTX) | 0.8 | $7.9M | +53% | 263k | 30.10 |
|
| Ionis Pharmaceuticals (IONS) | 0.8 | $7.4M | +8% | 213k | 34.96 |
|
| Cytokinetics Com New (CYTK) | 0.7 | $7.0M | -17% | 149k | 47.04 |
|
| Apellis Pharmaceuticals (APLS) | 0.6 | $6.2M | -46% | 196k | 31.91 |
|
| Biontech Se Sponsored Ads (BNTX) | 0.6 | $6.0M | +3% | 53k | 113.95 |
|
| Iqvia Holdings (IQV) | 0.6 | $5.7M | -39% | 29k | 196.51 |
|
| Nuvalent Inc-a (NUVL) | 0.6 | $5.7M | -19% | 73k | 78.28 |
|
| Universal Hlth Svcs CL B (UHS) | 0.6 | $5.5M | +286% | 31k | 179.42 |
|
| Glaukos (GKOS) | 0.6 | $5.5M | -67% | 37k | 149.94 |
|
| Nurix Therapeutics (NRIX) | 0.6 | $5.5M | -3% | 290k | 18.84 |
|
| Encompass Health Corp (EHC) | 0.5 | $5.2M | -8% | 56k | 92.35 |
|
| Xencor (XNCR) | 0.5 | $4.5M | -3% | 196k | 22.98 |
|
| Novo-nordisk A S Adr (NVO) | 0.4 | $4.3M | -50% | 50k | 86.02 |
|
| Insmed Com Par $.01 (INSM) | 0.4 | $4.2M | -52% | 62k | 69.04 |
|
| Esperion Therapeutics (ESPR) | 0.4 | $4.2M | -3% | 1.9M | 2.20 |
|
| Alnylam Pharmaceuticals (ALNY) | 0.4 | $4.0M | -66% | 17k | 235.31 |
|
| Krystal Biotech (KRYS) | 0.4 | $3.7M | +39% | 24k | 156.66 |
|
| Viking Therapeutics (VKTX) | 0.4 | $3.6M | -12% | 90k | 40.24 |
|
| Immunovant (IMVT) | 0.4 | $3.6M | -40% | 145k | 24.77 |
|
| Geron Corporation (GERN) | 0.4 | $3.5M | 1.0M | 3.54 |
|
|
| Arcellx Common Stock (ACLX) | 0.3 | $3.3M | +35% | 44k | 76.69 |
|
| Merus N V (MRUS) | 0.3 | $3.1M | -6% | 75k | 42.05 |
|
| Syndax Pharmaceuticals (SNDX) | 0.3 | $3.1M | -10% | 232k | 13.22 |
|
| Mirum Pharmaceuticals (MIRM) | 0.3 | $3.0M | -29% | 74k | 41.35 |
|
| Arvinas Ord (ARVN) | 0.3 | $3.0M | +19% | 156k | 19.17 |
|
| Annexon (ANNX) | 0.3 | $2.8M | -3% | 543k | 5.13 |
|
| Charles River Laboratories (CRL) | 0.3 | $2.7M | -60% | 15k | 184.60 |
|
| Kura Oncology (KURA) | 0.3 | $2.7M | +88% | 315k | 8.71 |
|
| Astrana Health Com New (ASTH) | 0.3 | $2.5M | NEW | 80k | 31.53 |
|
| Dianthus Therapeutics (DNTH) | 0.3 | $2.5M | -24% | 114k | 21.80 |
|
| Transmedics Group (TMDX) | 0.2 | $2.4M | -16% | 38k | 62.35 |
|
| Privia Health Group (PRVA) | 0.2 | $2.4M | +27% | 121k | 19.55 |
|
| Medpace Hldgs (MEDP) | 0.2 | $2.3M | -9% | 6.8k | 332.23 |
|
| Alkermes SHS (ALKS) | 0.2 | $2.2M | -41% | 78k | 28.76 |
|
| Bruker Corporation (BRKR) | 0.2 | $2.1M | -18% | 36k | 58.62 |
|
| Ideaya Biosciences (IDYA) | 0.2 | $2.1M | -35% | 82k | 25.70 |
|
| Relay Therapeutics (RLAY) | 0.2 | $1.9M | 460k | 4.12 |
|
|
| Immunocore Hldgs Ads (IMCR) | 0.2 | $1.7M | 58k | 29.50 |
|
|
| Pliant Therapeutics (PLRX) | 0.2 | $1.5M | -3% | 116k | 13.17 |
|
| Xenon Pharmaceuticals (XENE) | 0.1 | $1.4M | 35k | 39.20 |
|
|
| Avantor (AVTR) | 0.1 | $1.3M | +40% | 62k | 21.07 |
|
| Repligen Corporation (RGEN) | 0.1 | $1.3M | -10% | 9.0k | 143.94 |
|
| Inmune Bio Ord (INMB) | 0.1 | $833k | 178k | 4.67 |
|
|
| Amgen (AMGN) | 0.1 | $782k | 3.0k | 260.64 |
|
|
| Igm Biosciences (IGMS) | 0.1 | $770k | -32% | 126k | 6.11 |
|
| Acadia Healthcare (ACHC) | 0.1 | $545k | -86% | 14k | 39.65 |
|
| Bio-techne Corporation (TECH) | 0.0 | $216k | -85% | 3.0k | 72.03 |
|
Past Filings by Rhenman & Partners Asset Management AB
SEC 13F filings are viewable for Rhenman & Partners Asset Management AB going back to 2013
- Rhenman & Partners Asset Management AB 2024 Q4 filed Feb. 13, 2025
- Rhenman & Partners Asset Management AB 2024 Q3 filed Nov. 13, 2024
- Rhenman & Partners Asset Management AB 2024 Q2 filed Aug. 13, 2024
- Rhenman & Partners Asset Management AB 2024 Q1 filed May 14, 2024
- Rhenman & Partners Asset Management AB 2023 Q3 restated filed Nov. 13, 2023
- Rhenman & Partners Asset Management AB 2023 Q3 filed Nov. 9, 2023
- Rhenman & Partners Asset Management AB 2023 Q2 filed Aug. 11, 2023
- Rhenman & Partners Asset Management AB 2023 Q1 filed May 12, 2023
- Rhenman & Partners Asset Management AB 2022 Q4 filed Feb. 13, 2023
- Rhenman & Partners Asset Management AB 2022 Q3 filed Nov. 14, 2022
- Rhenman & Partners Asset Management AB 2022 Q2 filed Aug. 12, 2022
- Rhenman & Partners Asset Management AB 2022 Q1 filed May 13, 2022
- Rhenman & Partners Asset Management AB 2021 Q4 filed Feb. 11, 2022
- Rhenman & Partners Asset Management AB 2021 Q3 filed Nov. 12, 2021
- Rhenman & Partners Asset Management AB 2021 Q2 filed Aug. 13, 2021
- Rhenman & Partners Asset Management AB 2021 Q1 filed May 14, 2021